Search results
Results from the WOW.Com Content Network
The successful treatment and management of HIV/AIDS is affected by a plethora of factors which ranges from successfully taking prescribed medications, preventing opportunistic infection, and food access etc. Food insecurity is a condition in which households lack access to adequate food because of limited money or other resources.
The human immunodeficiency virus (HIV) [8] [9] [10] is a retrovirus [11] that attacks the immune system.It is a preventable disease. [5] It can be managed with treatment and become a manageable chronic health condition. [5]
Antiretroviral drugs are used to manage HIV/AIDS.Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden.. Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
Tablets of Truvada, a tenofovir/emtricitabine combination used for HIV pre-exposure prophylaxis. Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is the use of antiviral drugs as a strategy for the prevention of HIV/AIDS by people that do not yet have HIV/AIDS. [1]
Zidovudine (ZDV), also known as azidothymidine (AZT), was the first antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. [ 6 ]
The abbreviation PrEP now typically refers to pre-exposure prophylaxis for HIV prevention, the use of antiviral drugs as a strategy for the prevention of HIV/AIDS. [2] PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who have a higher risk of acquiring HIV, including sexually active adults at increased risk of contracting HIV, people who engage in ...
If the drugs are not taken, a body is heading toward AIDS, the final stage of infection. FILE – American doctor Mark Ottenweller, right, examines AIDS patient Yacouba Guengane in his clinic in ...
Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen. Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events.